Journal article

Psychiatric-related safety outcomes of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: A phase 3, randomized, double-blind, multicentre, parallel-group, placebo- and active-controlled, dose-optimized study in Europe

ML Lecendreux, RW Dittmann, M Gasior, T Banaschewski, R Civil, R Bloomfield, L Squires, DR Coghill

Neuropsychiatrie de l Enfance et de l Adolescence | Elsevier BV | Published : 2012